ArticleCancer immunology, immunotherapy : CII2024

Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.

Joanna Baginska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.